Abstract TP412: Neurologic Severity and Functional Outcome Are Not Affected By Prestroke Antiplatelets Use in Patients with First-ever Ischemic Stroke
Objectives: We aimed to investigate whether taking antiplatelets before the occurrence of ischemic stroke is associated with lessened initial neurologic severity or better outcome at 3 months compared to taking no antiplatelets.
Methods: We consecutively included first-ever ischemic stroke patients within 72 hours of onset from Feb 2008 to Sept 2010. Demographics, stroke subtype and risk factors were obtained. Initial NIHSS scores and mRS at 3 months were used to compare initial severity and functional outcome (good outcome, mRS 0 or 1) between prestroke antiplatelets users and non-users. We performed multivariate analysis using linear regression for initial NIHSS score and logistic regression for good functional outcome. Antiplatelet users were defined as those taking antiplatelets at least for 7 days before stroke onset.
Results: Total 353 patients were included for this study. Compared to non-users, age (years) was older (67 vs. 71, p=0.02) and more patients (%) had hypertension (63 vs. 92, p<0.01), diabetes (42 vs. 64, p<0.01), atrial fibrillation (4 vs. 12, p<0.01), and history of coronary heart disease (3 vs. 16, p<0.01) in prestroke antiplatelets users. Mean initial NIHSS scores were not different between the two groups (4 vs. 5, p=0.1) and less prestroke antiplatelets users had good functional outcome than non-users (116 (45%) vs. 30 (32%), p=0.03). In multivariate analysis, old age, diabetes, atrial fibrillation and absence of hypertension were significantly associated with high initial NIHSS score. Old age (RR, 95% CI; 0.99, 0.96~1.0, p=0.03) and initial NIHSS score (0.67, 0.60~0.75, p<0.01) were related to good functional outcome. Prestroke antiplatelets was associated with neither initial NIHSS score nor good functional outcome.
Conclusion: In patients with first-ever ischemic stroke, prestroke antiplatelets was not associated with initial stroke severity and functional outcome at 3 months.
- © 2012 by American Heart Association, Inc.